Free tool
FAERS Monitor: Beovu
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761125 or its brand name (Beovu, Brolucizumab-Dbll). Reports on generic versions are filed under their own applications.
Reports
3,648
Serious
2,878
79% of reports
Hospitalization
283
Death reported
246
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- visual impairment573
- vitreous floaters558
- vision blurred536
- eye inflammation447
- visual acuity reduced435
- retinal vasculitis384
- uveitis364
- vitritis358
- eye pain319
- blindness247
- anterior chamber cell233
- ocular hyperaemia224
- vitreous opacities223
- drug ineffective221
- keratic precipitates217
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 185 |
| 2020 | 1,252 |
| 2021 | 845 |
| 2022 | 461 |
| 2023 | 341 |
| 2024 | 310 |
| 2025 | 168 |
| 2026 | 84 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,511 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| keratic precipitatesSignal | 217 | 4853.4 | 4063.7 | 569,194 |
| anterior chamber cellSignal | 233 | 2795.2 | 2398.6 | 436,575 |
| retinal vasculitisSignal | 384 | 2745.8 | 2442.4 | 712,089 |
| vitreous opacitiesSignal | 223 | 2068.8 | 1781.5 | 337,759 |
| vitritisSignal | 358 | 1381.8 | 1237.1 | 397,459 |
| vitreous floatersSignal | 558 | 347.0 | 320.6 | 181,336 |
| eye inflammationSignal | 447 | 283.3 | 259.1 | 119,653 |
| uveitisSignal | 364 | 159.0 | 144.0 | 55,484 |
| visual acuity reducedSignal | 435 | 76.5 | 70.0 | 31,968 |
| blindnessSignal | 247 | 35.2 | 31.2 | 8,130 |
| eye painSignal | 319 | 32.8 | 29.5 | 9,767 |
| ocular hyperaemiaSignal | 224 | 27.3 | 24.1 | 5,644 |
| visual impairmentSignal | 573 | 26.8 | 24.8 | 14,212 |
| vision blurredSignal | 536 | 22.6 | 20.9 | 11,068 |
| drug ineffective | 221 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.